23596-28-3

Basic information

• Product Name: 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI)
• Synonyms: 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI);1H-Pyrrolo[3,2-c]pyridine, 2,3-dihydro-;2,3-dihydro-1H-pyrrolo[3,2-c]pyridine;1H,2H,3H-Pyrrolo[3,2-c]pyridine
• CAS NO: 23596-28-3
• Molecular Formula: C₇H₈N₂
• Molecular Weight: 120.16
• Product Categories: PYRROLIDINE
• Mol File: 23596-28-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 264.907 °C at 760 mmHg
• Flash Point: 114.012 °C
• Appearance: /
• Density: 1.115 g/cm³
• PKA: 9.91±0.20(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI)(23596-28-3)
• EPA Substance Registry System: 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI)(23596-28-3)

Safety Data

• Hazardous Substances Data: 23596-28-3(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI) is a chemical compound with a fused pyrrolopyridine ring structure. It is an organic compound that is described as a heterocycle, meaning it contains atoms of at least two different elements in its ring. 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI) is classified as a nitrogen-containing heterocyclic compound, and it is used in organic synthesis and drug discovery. It has potential applications in the pharmaceutical industry for the development of new drugs due to its unique structure and reactivity. The compound's properties and potential uses make it an important target for further study and exploration in the field of medicinal chemistry and chemical research.

Upstream product

• 271-34-1 5-azaindole 
• 219834-80-7 (tert-butoxy)-N-[3-(2-hydroxyethyl)(4-pyridyl)]carboxamide 
• 219834-81-8 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 98400-69-2 N-(4-pyridyl) t-butyl carbamate 
• 504-24-5 4-aminopyridine 

Downstream Products

• 1198293-18-3 (2,3-dihydro-pyrrolo[3,2-c]pyridin-1-yI)-(4-methoxy-8-nitro-dibenzofuran-1-yl)-methanone 
• 1198293-14-9 (4-difluoromethoxy-8-nitro-dibenzofuran-1-yl)-(2,3-dihydropyrrolo[3,2-c]pyridin-1-yl)-methanone 
• 1198293-21-8 (2,3-dihydro-pyrrolo[3,2-c]pyridin-1-yl)-(1-methoxy-9-methyl-6-nitro-9H-carbazol-4-yl)-methanone 
• 1158918-32-1 5-(6-(2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-1-carbonyl)pyrimidin-4-ylamino)-1,3-dihydro-spiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 760947-16-8 4-(2,3-dihydro-pyrrolo[3,2-c]pyridin-1-yl)-3-fluoro-quinoline 
• 219834-98-7 1-(1-methyl-2-pyrrolino[2,3-d]pyridin-7-yl)-2-naphthyl (trifluoromethyl)sulfonate 
• 219834-92-1 1-(1-methyl(2-pyrrolino[2,3-d]pyridin-7-yl))-2-(phenylmethoxy)naphthalene 

Relevant articles and documents

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION

The present invention relates to novel heterocyclic compounds of general formula (I), which are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors, pharmaceutical compositions containing them, and processes for their preparation. These novel PDEs are useful in treating allergic and inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) and for inhibiting the production of Tumor Necrosis Factor(TNF-α).